Full-Time

Director, Gross-to-Net Strategy & Policy Analytics

Otsuka Pharmaceutical

Otsuka Pharmaceutical

1,001-5,000 employees

Global pharma maker of Abilify

Compensation Overview

$186.5k - $278.9k/yr

+ Incentive opportunity

Remote in USA

Remote

Bachelor's, Master's, MBA

Category
Finance & Banking (1)
Required Skills
SAP Products
Anaplan

Get referred to Otsuka Pharmaceutical

See people who can refer or advise you

Requirements
  • The candidate must have 8+ years of experience in pharmaceutical finance, pricing, gross-to-net, or market access analytics.
  • Direct ownership of gross-to-net or revenue forecasting for U.S. products is preferred.
  • The candidate must have a deep understanding of U.S. channel economics and government and commercial program mechanics, including Medicaid, Medicare Part D and coverage gap, commercial rebates, 340B, chargebacks, and wholesaler agreements.
  • The candidate must have hands-on experience with financial planning and revenue management systems such as Anaplan, Model N, or SAP, and be comfortable working with large, complex data sets.
  • The candidate must have a strong grasp of the U.S. pricing and policy landscape, including the Inflation Reduction Act, inflation penalties, MFP, MFN concepts, and state transparency, and their implications for list price, contracting, and gross-to-net.
  • The candidate must be able to lead cross-functional decision-making with Finance, Policy, Market Access, Brand, and Global stakeholders in a matrix organization.
  • The candidate must have advanced analytical and modeling skills, including scenario and sensitivity analysis, with a track record of translating complex analytics into clear recommendations for senior leaders.
  • The candidate must have a bachelor's degree in Finance, Economics, Mathematics, Pharmacy, or a related field.
Responsibilities
  • Develop and recommend end-to-end U.S. gross-to-net forecasting for all inline products, including RF and budget submissions, long-range planning, and monthly updates, using Anaplan and home-grown models as core tools.
  • Provide gross-to-net inputs and assumptions to Finance and Accounting for accrual management and external financial reporting, ensuring alignment with the close calendar and external audit requirements.
  • Lead the design, enhancement, and execution of gross-to-net models at the channel and product level, including Medicaid, Medicare, commercial rebates, wholesaler and distribution, returns, copay, 340B, cash discounts, and disputes, and own consolidated portfolio-level output.
  • Run scenario analyses and ranges around base-case forecasts to quantify risk and opportunity, including shocks from policy changes, competitive events, and access shifts.
  • Partner with the U.S. Policy team to quantify the financial impact of current and proposed policies, including the Inflation Reduction Act, price appreciation caps, MFN concepts, and MFP and IRA selections, and advise on forecast treatment.
  • Lead recurring cross-functional gross-to-net governance with Finance, Gross-to-Net Accounting, Market Access Strategy, and Brand to align on volume, access, and rebate assumptions and monitor monthly trends, including 340B volatility.
  • Use modeling to predict future impacts to ASP, Medicaid URA, and 340B Price, and make recommendations for annual price changes.
  • Develop and maintain payer- and access-based gross-to-net drivers, partnering with Market Access Strategy to refresh payer-level access and rebate assumptions and integrate them into forecasts.
  • Oversee implementation, maintenance, and continuous improvement of the Anaplan gross-to-net planning environment, including automated data interfaces from Model N and external partners, and manage external consultants supporting the platform.
  • Establish monitoring and diagnostics for gross-to-net performance, including daily, weekly, and monthly KPI review, variance analysis against prior forecasts, and deep dives such as 340B spikes with Government Pricing and Audit teams.
  • Provide U.S. gross-to-net and pricing perspectives in senior-level forums, including U.S. leadership, Global Finance, and the Pricing Committee, and communicate uncertainty, ranges, and key value drivers as the portfolio scales.
  • Partner with Finance through close cycles to ensure accurate balance sheet accruals and reconciliation.
Desired Qualifications
  • An MBA, MS in Finance, or similar advanced degree is preferred.
Otsuka Pharmaceutical

Otsuka Pharmaceutical

View

Otsuka Pharmaceutical develops and markets medicines and health products worldwide, including prescription drugs and nutraceutical beverages. Its product lineup ranges from pharmaceutical treatments such as Abilify (an antipsychotic) to consumer health drinks like Pocari Sweat, which helps replenish electrolytes. Abilify works as a psychiatric medication used to treat conditions such as schizophrenia and bipolar disorder, while Pocari Sweat is an ion-replacement beverage designed to restore minerals and fluids after activity or heat. The company differentiates itself through a long history dating back to its founding in 1921, a broad, globally scaled portfolio spanning drugs and health beverages, and a focus on health improvements across populations. Its stated goal is to create new products for better health worldwide.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1921

Get referred to Otsuka Pharmaceutical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Otsuka closed Transcend in June 2026, expanding psychiatry beyond Abilify dependence.
  • DAWNZERA gained EU authorization in January 2026, opening paid sales across 27 countries.
  • Paradise uRDN and CART BP pro broaden Japan's hypertension platform and device distribution.

What critics are saying

  • SIMTRIYO waits on DEA scheduling, delaying revenue until late 2026.
  • VOYXACT's accelerated approval depends on confirmatory kidney-outcome data; failure risks withdrawal.
  • Transcend's TSND-201 PTSD program remains clinical-stage, risking a $1.225 billion write-down.

What makes Otsuka Pharmaceutical unique

  • Otsuka pairs CNS, nephrology, and device assets across Japan, US, and Europe.
  • SIMTRIYO gives Otsuka a first-in-class ADHD stimulant franchise after July 2026 FDA approval.
  • DAWNZERA and VOYXACT anchor rare-disease pipelines with global reimbursement and accelerated paths.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Tuition Reimbursement

Student Loan Assistance

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Associated Press
Jul 25th, 2026
FDA approves Otsuka's Simtriyo, first-in-class ADHD treatment for adults and children 6+

Otsuka Pharmaceutical has received FDA approval for SIMTRIYO (centanafadine), the first norepinephrine, dopamine, serotonin reuptake inhibitor for treating ADHD in adults and children aged six years and older weighing at least 20kg. The once-daily extended-release capsule will be available later this year following DEA scheduling. The approval is based on four Phase 3 clinical trials showing statistically significant improvements in ADHD symptoms compared to placebo, with benefits observed as early as week one. Common side effects include decreased appetite, nausea, rash, and headache. ADHD affects approximately 7 million children and 15.5 million adults in the US. The drug carries boxed warnings for suicidal ideation in pediatric patients and potential for abuse and addiction.

SonoThera
Jun 10th, 2026
SonoThera Closes Oversubscribed $125 Million Series B Financing to Advance Clinical Development of Ultrasound-Mediated Nonviral Genetic Medicines - SonoThera

SAN FRANCISCO–SonoThera, a biotechnology company developing next-generation genetic medicines to address the root causes of disease, today announced the closing of an oversubscribed $125 million Series B financing round to advance its lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD) into the clinic and expand its pipeline of targeted, redosable genetic medicines.

Dealroom.co
Mar 27th, 2026
Transcend Therapeutics company information, funding & investors

Transcend Therapeutics, developing the next generation of psychoactive compounds for neuropsychiatry focused on patient access. Here you'll find information about their funding, investors and team.

Fierce Biotech
Mar 27th, 2026
Otsuka buys Transcend Therapeutics for $700M upfront in psychiatric drugs deal

Otsuka Pharmaceutical has acquired Transcend Therapeutics for $700 million upfront through its subsidiary Otsuka America, with potential milestone payments of up to $525 million. The deal gives Otsuka access to Transcend's MDMA analogue for psychiatric conditions currently in development.

Associated Press
Mar 25th, 2026
Otsuka's Voyxact shows 82.5% hematuria improvement in IgA nephropathy trial at 48 weeks

Otsuka presented new Phase 3 VISIONARY trial data for VOYXACT (sibeprenlimab-szsi) in IgA nephropathy patients at the 2026 ISN World Congress of Nephrology. The analyses showed 82.5% of patients receiving sibeprenlimab achieved negative microscopic hematuria at week 48, compared with 52.6% on placebo. Median time to achieve hematuria negativity was nine weeks versus 24 weeks for placebo. VOYXACT, approved under accelerated approval in the US, is a monoclonal antibody that inhibits APRIL, a key driver in IgAN pathogenesis. Previously reported data showed the drug met its primary endpoint with a 51.2% placebo-adjusted reduction in proteinuria at nine months. The trial continues evaluating sibeprenlimab's effect on preserving kidney function over 24 months.